Alumis (NASDAQ:ALMS) Insider Sanam Pangali Sells 5,000 Shares of Stock

Alumis Inc. (NASDAQ:ALMS) insider Sanam Pangali sold 5,000 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $28.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider directly owned 11,111 shares in the company, valued at $311,108. This trade represents a 31.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Alumis Trading Up 1.7%

ALMS traded up $0.50 during trading on Wednesday, hitting $29.77. 2,712,999 shares of the company traded hands, compared to its average volume of 2,184,009. The company has a market cap of $3.80 billion, a PE ratio of -15.04 and a beta of -0.73. Alumis Inc. has a 1 year low of $3.24 and a 1 year high of $31.35. The stock’s 50-day simple moving average is $23.37 and its two-hundred day simple moving average is $23.18.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The firm had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%. Equities analysts expect that Alumis Inc. will post -2.87 EPS for the current year.

Hedge Funds Weigh In On Alumis

A number of large investors have recently made changes to their positions in the company. MPM Bioimpact LLC bought a new position in Alumis during the 4th quarter valued at about $23,443,000. Janus Henderson Group PLC purchased a new position in shares of Alumis during the first quarter valued at approximately $46,790,000. Orbimed Advisors LLC purchased a new position in shares of Alumis during the second quarter valued at approximately $5,779,000. Woodline Partners LP grew its stake in shares of Alumis by 809.7% during the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock valued at $6,987,000 after buying an additional 1,558,660 shares during the last quarter. Finally, Samsara Biocapital LLC grew its stake in shares of Alumis by 47.0% during the second quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after buying an additional 1,534,872 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. HC Wainwright cut shares of Alumis from a “buy” rating to a “neutral” rating and set a $25.00 target price on the stock. in a research report on Friday, May 15th. Wells Fargo & Company upped their price objective on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. Morgan Stanley reaffirmed an “overweight” rating and issued a $39.00 price objective on shares of Alumis in a research note on Friday, May 15th. Wall Street Zen cut Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Citigroup reissued a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.30.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.